Abstract
Hyperkalemia most commonly develops in patients with heart failure (HF) or chronic kidney disease (CKD). Sodium zirconium cyclosilicate (SZC) is a new selective potassium (K+) binder for the treatment of hyperkalemia. The aim of this study was to evaluate the cost-effectiveness of SZC versus usual care (consisting of calcium polystyrene sulfonate (CPS), lifestyle interventions, RAASi modifications, etc.) for the treatment of hyperkalemia among HF and CKD patients in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
